5 Key Takeaways

• 1

  Par Health USA voluntarily recalled 22 lots of argatroban injection nationwide after detecting particulate contamination.

• 2

  The particles included cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel.

• 3

  The company warned that affected injections could cause pulmonary emboli, vascular occlusion with tissue or organ damage, and venous inflammation that may lead to clot formation.

• 4

  The recall covers 20 lots under NDC 42023-182-01 and 2 lots under NDC 42023-182-89, distributed to US wholesalers and hospitals from December 30, 2024, through May 5, 2026.

• 5

  Wholesale distributors and hospital pharmacies should immediately stop using and distributing affected lots, and notify downstream recipients if products were redistributed.